PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 87

Change

-1.07 (-1.21)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-23 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.88 (-0.57%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

-0.31 (-0.42%)

USD 3.01B
FXH First Trust Health Care AlphaD..

-0.26 (-0.23%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.36 (-0.40%)

USD 0.23B
IDNA iShares Genomics Immunology an..

-0.46 (-1.85%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.94 (-2.41%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-0.13 (-0.13%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.22 (-0.76%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-1.75 (-2.72%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-1.14 (-3.89%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.32% 81% B- 70% C-
Dividend Return 0.76% 69% C- 16% F
Total Return 15.09% 95% A 65% D
Trailing 12 Months  
Capital Gain 18.38% 52% F 58% F
Dividend Return 1.05% 56% F 13% F
Total Return 19.43% 43% F 52% F
Trailing 5 Years  
Capital Gain 52.18% 62% D 72% C
Dividend Return 4.18% 61% D- 12% F
Total Return 56.36% 57% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.55% 57% F 60% D-
Dividend Return 7.14% 57% F 55% F
Total Return 0.59% 58% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.89% 67% D+ 70% C-
Risk Adjusted Return 55.40% 67% D+ 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike